Introduction Opioids are one of the most important and effective drug classes in pain medicine with a key role in most medical fields. The increase of opioid prescription over time has led to higher numbers of prescription opioid misuse, abuse and opioid-related deaths in most developed OECD (Organisation for Economic Co-operation and Development) countries around the world. Whilst reliable data on the prevalence of opioid treatment is accessible for many countries, data on Germany specifically is still scarce. Considering Germany being the largest country in the European Union, the lack of evidence-based strategies from long-term studies is crucial. The aim of this work is to review and summarise relevant published literature on the prevalence of opioid prescription in Germany to adequately inform health policy strategies. Methods A systematic review of the epidemiology of opioid prescription in Germany was conducted, searching PubMed and Web of Science. Eligibility criteria were defined prior to conducting the search. Literature concerning Germany, published in English and German was included and the search was replicated by three independent researchers. Two levels of screening were employed. Disagreement was resolved by face-to-face discussion, leading to a consensus judgement. Results Our electronic search yielded 735 articles. Reviewing titles and abstracts yielded 19 relevant articles. Three authors examined each article’s full text more closely and determined that twelve papers should be included. Of the twelve identified studies—with publication dates ranging from 1985 to 2016—six were retrospective cross-sectional studies and six were retrospective repeated-measures cross-sectional studies. Sample sizes ranged from 92,842 to ≈ 11,000,000 participants. Data sources of included studies showed vast heterogeneity. The reviewed literature suggested an increase in the number of patients with opioid prescriptions and defined daily doses of opioids per recipient in Germany over time. The majority of opioid prescriptions was used for patients with non-cancer pain. Opioid use was more common in older people, women and in the north of Germany. Fentanyl was shown to be the most prescribed strong opioid in outpatient settings in Germany, despite not being the first-line choice for chronic pain conditions. All data published before 2000—but none of the more recent studies—suggested an insufficient treatment of pain using opioids. There were no signs for a current opioid epidemic in Germany. Conclusions Despite some limitations of the review and the heterogeneity of studies, it can be stated that the number of opioid prescriptions overall as well as the number of people receiving opioid treatment have increased over time. Most prescriptions were found to be for strong opioids and patients with non-cancer pain. Even though patterns of opioid prescription follow trends observed in other developed countries, there are...
Background In 2017, more than 1.1 million children were living with type 1 diabetes mellitus (T1DM) globally. The goal in paediatric diabetes therapy is reaching optimal glycaemic control as early as possible in order to avoid complications and early mortality without compromising the quality of life (QoL) of children. Several different insulin regimens are available for T1DM patients to reach this goal. Aims This review set out to analyse whether continuous subcutaneous insulin infusion (CSII) regimens are superior to multiple daily injection (MDI) therapy in T1DM youth regarding QoL. Additionally, it assessed glycaemic control and adverse events as secondary outcomes and discussed potential future public health implications and justifications for using CSII as a first-line therapy in diabetic youth. Methods A systematic review and random effects meta-analysis was performed on studies investigating the association between QoL and diabetes treatment regimen. Differences in adverse event rates between groups were analysed using a Mann-Whitney U test. Lastly, differences in glycaemic control were assessed using a random effects meta-analysis. Results QoL and glycaemic control was significantly better in CSII subjects at baseline and follow-up. No significant differences in adverse events were found between study groups. No significant changes over time could be shown for either QoL or glycaemic control. Conclusion CSII proved to provide similar or slightly better outcomes in all analysed fields. This is consistent with previous research. However, to make credible recommendations, better-designed studies are needed to investigate the impact of CSII in children.
Objectives: To determine and compare the benefit of binaural hearing rehabilitation via cochlear implantation (CI) on speech perception, assessment of auditory abilities, tinnitus distress, health-related quality of life (HRQoL) and psychological comorbidities in patients suffering from asymmetric hearing loss (AHL) as well as bilaterally-deafened and sequentially bilaterally-implanted patients. Methods: 53 patients were implanted between 2011 and 2016. 24 AHL patients were implanted unilaterally, using a hearing aid on the other side. 29 bilaterally-deafened patients were sequentially implanted bilaterally. Speech perception, subjective hearing quality, HRQoL, tinnitus distress, anxiety, depressiveness, perceived stress level and coping abilities were evaluated before implantation, as well as 6 and 24 months postoperatively. Results: Before CI, AHL and bilaterally-deaf patients showed significant differences regarding assessment of auditory abilities, speech discrimination, tinnitus distress and HRQoL. 24 months after CI both groups significantly improved in those scales. We could not find a significant difference between the groups after 2 years. Tinnitus distress significantly decreased 6 and 24 months postoperatively in both groups. Conclusions: This study demonstrates the long-term benefit of binaural hearing rehabilitation in AHL and bilaterally-deaf patients not only regarding speech perception but also HRQoL, tinnitus distress and subjective hearing quality. Bilaterally-deafened patients present lower scores preoperatively, but they did not differ from AHL patients 2 years after CI. Up to now, this is the first study evaluating the outcome of CI in AHL patients compared to bilaterally-implanted patients and demonstrating the benefit of binaural hearing rehabilitation in these specific groups.
Zusammenfassung Hintergrund Das unerwartete Eintreffen eines kritisch kranken Kindes, ohne vorherige rettungsdienstliche Versorgung oder Anmeldung, stellt in der Kindernotaufnahme eine seltene Fallkonstellation dar, wodurch entsprechende Routine bei der Versorgung fehlen kann. Eine Erhöhung der Handlungssicherheit kann durch Anwendung einer Prozessrisikoanalyse gelingen, welche als etablierte Methode des klinischen Risikomanagements Abläufe präventiv nach möglichen Risiken der bestehenden (Behandlungs‑)Prozesse untersucht und abwehrende Maßnahmen ableitbar macht. Methode Die Prozessrisikoanalyse soll exemplarisch anhand des Beispiels „Unerwartete Versorgung eines kritisch kranken Kindes“ durchgeführt und vorgestellt werden. Eine kleinteilige Aufgliederung in Haupt- und Teilabschnitte erlaubt die Erstellung eines prozessbezogenen Risikoprofils, auf Grundlage dessen eine Priorisierung von Risiken nach Kriterien wie Eintrittswahrscheinlichkeit und potenziellem Schadensausmaß vorgenommen wird. Dadurch werden abwehrende Maßnahmen nach Dringlichkeit ableitbar, welche den hier untersuchten Patientenpfad optimieren können. Schlussfolgerung Durch Prozessrisikoanalysen von klinischen Abläufen können bestehende Risiken detektiert und potenzielle Maßnahmen zur Reduktion dargestellt werden. Für den exemplarisch beschriebenen Fall konnten vier prozessbezogene Hauptrisiken (Untertriagierung, Fehl‑/Nichtdiagnostik, Fehler in Medikation und Auswahl von Devices, unzureichende Infrastruktur und interdisziplinäre Abstimmung) aufgezeigt werden. Daraus folgend wurden potenziell abwehrende Maßnahmen beschrieben und die notwendigen Ressourcen abgeschätzt.
suggests that class-based identities can also lead to density associations with mental health, but that it is the symbolic signifiers of class, and not material aspects, which activate class identities in this way.
Zusammenfassung Einleitung Obwohl Schmerzen der häufigste Grund für eine Vorstellung in der Notaufnahme sind, ist ihre Erfassung und Therapie sehr heterogen organisiert und wird vielfach von Patienten als unzureichend beschrieben. Eine spezielle Leitlinie existiert bislang nicht und so wird beispielsweise die Delegation an die Notfallpflege nach Standard Operating Procedure (SOP) sehr unterschiedlich gehandhabt. Methode Mithilfe einer Umfrage erfolgte eine Ist-Analyse zur Organisation und Durchführung der akuten Schmerztherapie in deutschen Notaufnahmen. 18 Fragen wurden onlinebasiert erstellt und über das Notaufnahmeverzeichnis der DGINA e. V. (Deutsche Gesellschaft für interdisziplinäre Notfall- und Akutmedizin) und DIVI e. V. (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin) an die Leiter von 951 deutschen Notaufnahmen verschickt. Ergebnis Es konnten 166 vollständige Fragebögen ausgewertet werden. Die Erfassung der Schmerzen erfolgt bei 77,7 % der Notaufnahmen innerhalb der ersten 10 min nach Erstkontakt, meist mit der numerischen Rating-Skala (46,4 %). Obwohl 17,7 % nicht dauerhaft ärztlich besetzt sind, dürfen in insgesamt 32,5 % der Notaufnahmen Pflegekräfte keine eigenständige Schmerztherapie durchführen. Eine spezielle SOP gab es nur in 44,8 % der befragten Notaufnahmen. Die am häufigsten verwendeten Analgetika sind Piritramid und Morphin sowie Metamizol und Ibuprofen. Schlussfolgerung Eine entsprechende nationale Leitlinie könnte Handlungssicherheit geben und als Grundlage für angepasste, örtliche SOP helfen, Verzögerungen bei der akuten Schmerztherapie zu vermeiden.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.